IXHL · Incannex Healthcare Inc. · Financials
Market Cap
$39.00M
Shares
11.96M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$86K
+616.7%
FY2025
Net Income
-$46.89M
-154%
FY2025
Gross Margin
51.94%
+26.4pp
FY2021
Operating Margin
-27661.63%
+222680pp
FY2025
Diluted EPS
-$40.50
-17.4%
FY2025
Operating Cash Flow
-$12.51M
+21%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $86K | $12K | — | — | $1.9M | $604.88K | |
| — | — | $172K | — | — | — | — | |
| — | — | — | — | $6338 | $911.97K | $450.35K | |
| — | — | — | — | — | $985.63K | $154.54K | |
| — | — | — | — | — | 51.94% | 25.55% | |
| $7.42M | $10.75M | $12.88M | $6.31M | $5.37M | $4.75M | $2.11M | |
| $17.94M | $13.13M | $17.17M | $8.01M | $280.97K | $99.09K | $457.67K | |
| $251K | $246K | $103K | $88K | — | — | — | |
| $25.37M | $23.88M | $30.05M | $49.67M | — | — | — | |
| -$25.37M | -$23.79M | -$30.04M | -$49.67M | — | — | — | |
| — | -27661.63% | -250341.67% | — | — | — | — | |
| -$25.11M | -$23.54M | -$29.94M | -$49.58M | — | — | — | |
| $349K | $303K | — | — | — | — | — | |
| — | $62K | $206K | $241K | — | — | — | |
| -$23.05M | -$23.1M | $11.61M | $857K | — | — | — | |
| -$48.41M | -$46.89M | -$18.43M | -$48.81M | -$14.9M | -$11.37M | -$3.93M | |
| — | — | $30K | — | — | — | — | |
| -$48.41M | -$46.89M | -$18.46M | -$48.81M | -$14.9M | -$11.37M | -$4.7M | |
| — | -54517.44% | -153825% | — | — | -599.33% | -776.62% | |
| -$48.58M | -$46.68M | -$18.54M | -$51.1M | — | — | — | |
| USD/shares | -$17.26 | -$40.50 | -$34.50 | -$99.60 | -$37.50 | -$34.80 | -$20.70 |
| USD/shares | -$17.26 | -$40.50 | -$34.50 | -$99.60 | -$37.50 | -$34.80 | -$17.10 |
| shares | — | 1.15M | 538.81K | 512.82K | — | — | — |
| shares | — | 1.15M | 538.81K | 512.82K | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.16×
EV/EBIT
—
Peer median 8.54×
P/E (TTM)
—
Peer medians compare against the 41 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).